10-Q: Invivyd Narrows Losses, Advances VYD2311 with FDA Alignment

Invivyd, a biopharmaceutical company, reported significantly reduced net losses and increased product revenue in Q3 2025, while advancing its VYD2311 COVID-19 prevention program with positive FDA feedback.

Summary

• Net loss for the three months ended September 30, 2025, was $10.47 million, a substantial reduction from $60.74 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $41.42 million, down from $151.48 million for the nine months ended September 30, 2024.
• Product revenue, net, increased to $13.13 million for Q3 2025 from $9.30 million in Q3 2024, and to $36.22 million for the nine months ended September 30, 2025, from $11.56 million in the same period of 2024.
• Research and development (R&D) expenses decreased significantly to $8.05 million for Q3 2025 from $57.85 million in Q3 2024, and to $28.26 million for the nine months ended September 30, 2025, from $119.34 million in the same period of 2024.
• Selling, general and administrative (SG&A) expenses increased to $15.02 million for Q3 2025 from $12.96 million in Q3 2024, but slightly decreased to $48.36 million for the nine months ended September 30, 2025, from $48.97 million in the same period of 2024.
• Cash and cash equivalents stood at $84.97 million as of September 30, 2025, up from $69.35 million at December 31, 2024.
• The company announced positive full Phase 1/2 clinical data for VYD2311 in June 2025, demonstrating safety and favorable pharmacokinetics.
• In August 2025, the company announced FDA alignment on a compact and rapid pathway for potential Biologics License Application (BLA) approval for VYD2311 for COVID-19 prevention.
• The FDA cleared the Investigational New Drug (IND) application for VYD2311 in October 2025, advancing the REVOLUTION clinical program, which includes two Phase 3 trials (DECLARATION and LIBERTY) expected to begin around year-end 2025.
• The company successfully completed an underwritten public offering in August 2025, raising approximately $53.5 million in net proceeds, and sold additional shares under an ATM facility in October 2025 for $28.9 million net.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern beyond one year without additional funding.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvements in reducing net loss and increasing product revenue. Key advancements in the VYD2311 clinical program, including FDA alignment on a rapid BLA pathway and upcoming Phase 3 trials, are highly positive. Successful capital raises have bolstered liquidity. However, the explicit 'going concern' warning and continued accumulated deficit indicate ongoing financial challenges and reliance on future funding, tempering the overall positive sentiment.

Positives

• Net loss significantly decreased to $10.47 million in Q3 2025 from $60.74 million in Q3 2024, and to $41.42 million for the nine months ended September 30, 2025, from $151.48 million in the prior year period.
• Product revenue, net, increased by $3.8 million in Q3 2025 compared to Q3 2024, and by $24.6 million for the nine months ended September 30, 2025, compared to the same period in 2024, driven by PEMGARDA sales.
• Research and development expenses decreased substantially by $49.8 million in Q3 2025 and $91.0 million for the nine months ended September 30, 2025, indicating more efficient spending or completion of costly development phases.
• Positive full Phase 1/2 clinical data for VYD2311 for both safety and pharmacokinetics was announced in June 2025.
• FDA alignment on a compact and rapid pathway to potential BLA approval for VYD2311 for COVID-19 prevention, including immunocompromised individuals, was announced in August 2025.
• The FDA cleared the IND application for VYD2311 in October 2025, allowing the REVOLUTION clinical program to advance.
• Initiation of the BLA-enabling Phase 3 DECLARATION and Phase 3 LIBERTY clinical trials for VYD2311 is expected around year-end 2025, with top-line data anticipated mid-2026.
• The company formed the SPEAR Study Group in July 2025 to evaluate mAb therapy for Long COVID or Post-Vaccination Syndrome (PVS), indicating pipeline expansion.
• Successful capital raises through an underwritten public offering ($53.5 million net) and an ATM facility ($28.9 million net in October 2025) have improved liquidity and extended the cash runway.

Negatives

• The company continues to incur net losses, with an accumulated deficit of $943.4 million as of September 30, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern beyond one year without additional funding.
• Selling, general and administrative expenses increased by $2.0 million in Q3 2025 compared to Q3 2024, primarily due to headcount-related costs and stock-based compensation.
• Other income, net, decreased significantly to $0.6 million in Q3 2025 from $1.6 million in Q3 2024, primarily due to lower interest earned on invested cash balances.
• The company has not yet satisfied the net product revenue milestone required to be eligible to access proceeds from the $30 million Term Facility loan.
• The company faces ongoing risk of delisting from Nasdaq due to minimum bid price requirements, having received two deficiency notices in the past year, although compliance was regained.

Risks

• Inability to raise additional capital to fund operations, which could force delays, reductions, or elimination of research and development programs or commercialization efforts.
• Failure to obtain regulatory authorization or approval for product candidates beyond PEMGARDA's Emergency Use Authorization (EUA).
• Risks associated with market acceptance and commercialization of products.
• Competition from other products in the biopharmaceutical industry.
• Challenges in protecting proprietary intellectual property.
• Difficulties in complying with government regulations.
• Dependence on key personnel and the ability to attract and retain qualified employees.
• Reliance on third-party organizations for discovery, manufacturing, clinical, and commercial success of product candidates.
• Uncertainty of generating substantial revenue from product sales to fund operating expenses and capital requirements.
• Potential for inventory write-downs if actual market conditions are less favorable than projected or in the event of adverse FDA action.
• Inability to maintain compliance with Nasdaq continued listing standards, which could lead to delisting and adversely affect financing and trading of common stock.
• Failure to comply with the covenants or other terms of the Loan Agreement, potentially resulting in a default and acceleration of debt obligations.
• Inability to satisfy conditions in the Loan Agreement to draw down the amounts of the term loan facility.
• Restrictions imposed by the Loan Agreement that limit operational flexibility.
• Inability to generate sufficient cash flow from operations to service indebtedness.
• The temporary nature of PEMGARDA's EUA, which could be terminated or revoked sooner than expected.
• Uncertainty regarding the timing or amount of increased expenses or when, or if, profitability will be achieved or maintained.

Future Outlook

The company expects to continue incurring significant expenses and recognizing losses in the foreseeable future as it expands and progresses its research and development, manufacturing, and commercialization activities. Additional funding will be required through a combination of revenues, equity offerings, government or private-party grants, debt financings, or other capital sources to support continuing operations and growth strategy. The REVOLUTION clinical program for VYD2311, including the DECLARATION and LIBERTY trials, is expected to commence around year-end 2025, with top-line data anticipated mid-2026. The company may also consider additional studies in the REVOLUTION clinical program post-approval of VYD2311 and has initiated discovery efforts to expand its pipeline beyond SARS-CoV-2 to targets such as respiratory syncytial virus and measles.

Management Comments

• Our devotion is to delivering protection from serious viral infectious diseases, and our aim is to develop mAbs that could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and potentially expanding into other high-need indications.
• Our goal is to establish streamlined development pathways to efficiently introduce new mAb candidates targeting SARS-CoV-2.
• We actively monitor our stock price, and, as appropriate, will consider implementing available options to maintain or, if necessary, regain compliance with the Minimum Bid Price Requirement.
• We expect to finance our operations through a combination of contribution from revenues, equity offerings, government or private-party grants, debt financings or other capital sources, such as collaborations with other companies, strategic alliances or licensing arrangements to support our continuing operations and pursue our growth strategy.

Industry Context

The company operates within the biopharmaceutical industry, focusing on infectious diseases, particularly SARS-CoV-2. Its strategy aligns with the ongoing global health concern of COVID-19, especially for immunocompromised individuals, by developing new monoclonal antibodies (mAbs) for prevention and treatment. The expansion of its pipeline to include targets like respiratory syncytial virus and measles reflects a broader industry trend of diversifying infectious disease portfolios. The company's active SARS-CoV-2 variant monitoring and leveraging of third-party pseudoviral systems demonstrate a commitment to staying ahead of viral evolution, a critical aspect in the rapidly changing infectious disease landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global industry benchmarks.

Legal Proceedings

• As of September 30, 2025, the company was not a party to any material legal proceedings.

Related Party Transactions

• As of September 30, 2025, $0.7 million was due to Adimab (a principal stockholder) under the Adimab Assignment Agreement, Adimab Collaboration Agreement, Adimab Platform Transfer Agreement, and Adimab DNA Sequencing Services Agreement, included in accrued expenses.
• Expensed $0.5 million and $1.4 million in royalties to Adimab for the three and nine months ended September 30, 2025, respectively, as costs of product revenue under the Adimab Assignment Agreement.
• Recognized $0.6 million and $1.8 million of research and development expense for the three and nine months ended September 30, 2025, respectively, related to the quarterly fee under the Adimab Collaboration Agreement.
• Recognized $0.5 million and $1.5 million of research and development expense for the three and nine months ended September 30, 2025, respectively, related to the annual fee under the Adimab Platform Transfer Agreement.
• Recognized less than $0.1 million of research and development expense for the three and nine months ended September 30, 2025, respectively, with respect to services performed by Adimab under the Adimab DNA Sequencing Services Agreement.
• Tamsin Berry, a member of the company's board of directors, is a Limited Partner of Population Health Partners, L.P. (PHP), which holds the PHP Warrant.

Stakeholder Impact

• Shareholders face potential dilution from ongoing and future equity raises, and the risk of delisting from Nasdaq, but also potential for value creation from the advancement of the VYD2311 program and increased product revenue. The 'going concern' warning highlights significant financial risk.
• Employees benefit from continued operations and potential growth if funding is secured and programs advance, with stock-based compensation plans in place.
• Customers (patients and healthcare providers) will continue to have access to PEMGARDA (under EUA) and may benefit from the potential introduction of VYD2311 for COVID-19 prevention and future therapies for Long COVID/PVS.
• Suppliers and creditors, particularly WuXi Biologics with $25.6 million in commercial drug substance/product purchase obligations and $3.5 million for materials due in 2025, and Silicon Valley Bank as a lender, face risks related to the company's 'going concern' status if financial challenges are not resolved.

Next Steps

• Begin the DECLARATION (BLA-enabling, Phase 3) and LIBERTY (Phase 3 safety/co-administration) clinical trials for VYD2311 around year-end 2025.
• Anticipate top-line data from the DECLARATION and LIBERTY clinical trials mid-2026.
• Potentially conduct additional studies in the REVOLUTION clinical program post-approval of VYD2311.
• Continue to commercialize PEMGARDA.
• Advance the development of VYD2311.
• Establish streamlined development pathways for new mAb candidates targeting SARS-CoV-2.
• Continue discovery efforts to assess pipeline expansion beyond SARS-CoV-2, including potential targets such as respiratory syncytial virus and measles.
• Seek regulatory authorization or approval for any product candidates that successfully complete clinical trials.
• Pursue coverage and reimbursement for product candidates, if authorized or approved.
• Further develop and validate commercial-scale current Good Manufacturing Practices (cGMP) manufacturing processes.
• Maintain, expand, enforce, defend, and protect the intellectual property portfolio.
• Comply with regulatory requirements established by applicable regulatory authorities.
• Maintain and expand a sales, marketing, and distribution infrastructure for any authorized or approved product candidates.
• Hire and retain personnel, including research, clinical, development, manufacturing, quality control, quality assurance, regulatory, scientific, commercial, and other personnel.
• Incur additional legal, accounting, and other expenses associated with operating as a public company.
• Monitor SARS-CoV-2 variant activity as part of ongoing industrial virology efforts.
• Evaluate the potential impacts of ASU 2023-09 (Income Tax Disclosures) and ASU 2024-03 (Expense Disaggregation Disclosures).
• Work towards satisfying net product revenue milestones to become eligible to access Term B and Term C loans from Silicon Valley Bank.
• Actively monitor stock price and consider options to maintain or regain compliance with Nasdaq listing requirements.

Key Dates

Recommendation

While the company has demonstrated significant progress in reducing net losses, increasing product revenue, and advancing its VYD2311 program with positive FDA feedback, the explicit 'substantial doubt about its ability to continue as a going concern' is a critical concern. The successful capital raises provide a temporary improvement in liquidity, but the long-term financial viability remains uncertain without sustained profitability or further funding. The potential for VYD2311 is promising, but clinical trials are ongoing, and BLA approval is not guaranteed. Investors should hold and closely monitor the company's ability to secure additional funding, achieve VYD2311 milestones, and address its going concern status.

Keywords

Biopharmaceutical, SARS-CoV-2, COVID-19, Monoclonal Antibody, PEMGARDA, VYD2311, Clinical Trials, FDA, EUA, BLA, Long COVID, Post-Vaccination Syndrome, SPEAR Study Group, Research and Development, Financial Results, Going Concern, Capital Raise, Nasdaq Listing, Infectious Diseases